tbuckley/cabot-search huggingface dataset:
Influence of risk factors for renal cell carcinoma (RCC) on outcome of patients (pts) with metastatic disease (mRCC) treated with sunitinib (Su).
Authors: Raanan Berger, Daniel Keizman, Maya Ish-Shalom, Hans J. Hammers, Mario A. Eisenberger, Victoria J. Sinibaldi, Roberto Pili, Ben Boursi, Natalie Maimon, Maya Gottfried, Henry Hayat, Avivit Peer, Svetlana Kovel, Avishay Sella, Michael Anthony Carducci
Journal: Journal of Clinical Oncology (2012)

e15058 Background: Obesity, smoking, hypertension (HTN) and diabetes (DM) are risk factors for RCC development. Their presence has been associated with a worse outcome of therapy (tx) in various metastatic cancers. We sought to determine their influence on the progression free survival (PFS) and overall survival (OS) of Su tx in mRCC. Methods: We performed an international multicenter retrospective study of pts with mRCC, who were treated with Su. We analyzed the pre-tx status of smoking (active vs past vs never), BMI (obese= BMI≥30 vs overweight=BMI 25-29.9 vs normal weight= BMI &lt;25), HTN, DM, and known prognostic factors including past nephrectomy, clear cell vs non clear cell histology, initial diagnosis to Su tx initiation time, ≥ 2 metastasis (mets) sites, lung/liver/bone mets, ECOG performance status, anemia, calcium level &gt; 10, elevated alkaline phosphatase (AP), pre-tx neutrophil to lymphocyte ratio (NLR) &gt;3, Su induced HTN, use of angiotensin system inhibitors (ASIs), past cytokines/targeted tx, and median Su dose/cycle. PFS and OS were determined by the Kaplan-Meier method. Multivariate analyses using Cox Regression model were performed to determine their independent effect. Results: Between 2004-2011, 244 pts with mRCC were treated with Su. 51 pts were active smokers, 58 obese, 62 diabetic, and 145 had pre-tx HTN. In the entire pt cohort, median PFS was 9 months (mos) and OS 21 mos. Factors associated with PFS were active smoking (HR 2.29, p= 0.003, median PFS 4 vs 10 mos in past smokers vs 12 mos in never smokers), non clear cell histology (HR 1.7, p=0.042), pre-tx NLR &gt;3 (HR 1.92, p&lt;0.0001) and the use of ASIs (HR 0.58, p=0.03). Factors associated with OS were were active smoking (HR 1.85, p= 0.018, median OS 11 vs 25 mos in past smokers vs 27 mos in never smokers), AP (HR 1.9, p=0.017), pre-tx NLR &gt;3 (HR 2.5, p&lt;0.0001), and liver mets (HR 1.86, p=0.021). BMI, DM, and pre-tx HTN were not associated with PFS or OS. Conclusions: Active smoking may decrease the PFS and OS of pts with mRCC that are treated with Su. BMI, DM, and pre-tx HTN were not found to be associated with outcome. These results should be investigated prospectively, and if validated applied in clinical practice and clinical trials.
EXPRESS study: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors
Authors: A. Italiano, O. Le Saux, F. André, T. Filleron, D. Spaeth, P.-E. Heudel, L. Albiges, T. Bachelot, A. Gonçalves, J.-Y. Pierga, F. Barlesi, V. Boige, C. Lebbe, L. Mortier, J.-S. Frenel, O. Tredan, M. Jimenez, F. Legrand, C. Ferté
Journal: Annals of Oncology (2018)
Abstract 4213: Stool-derived eukaryotic RNA (seRNA) assay for noninvasive detection of colorectal cancer and high-risk adenomas
Authors: Erica K. Barnell, Yiming Kang, Katie M. Campbell, Kimberly R. Kruse, Andrew R. Barnell, Elizabeth M. Wurtzler
Journal: Cancer Research (2019)

Abstract Colorectal cancer (CRC) is the second leading cause of cancer related deaths in the United States. The high mortality rate for CRC is largely attributable to the frequency of late-stage diagnoses, caused by low patient compliance with screening guidelines. A novel nucleic acid extraction method that isolates stool-derived eukaryotic RNA (seRNA) has permitted development of a colorectal cancer stool diagnostic test (CRC-SDT) that uses a fecal immunochemical test (FIT) and 11 seRNA transcripts to serve as a reliable and noninvasive screening alternative to lower mortality associated with CRC. Stool samples were obtained from 190 individuals prior to undergoing a screening colonoscopy. Patients were diagnosed as either having colorectal cancer, having high-risk adenomas (high-grade dysplasia, villous growth pattern, or &amp;gt;1.0cm in size), or healthy (low-risk adenomas, benign polyps, and/or no findings on a colonoscopy). FITs were obtained for each sample. Samples that had a positive FIT were considered positive for the CRC-SDT. Samples that had a negative FIT underwent seRNA isolation, library preparation (Illumina TruSeq Targeted RNA) and subsequent sequencing (Illumina NextSeq 550). A random forest model was built using 11 transcripts that were differentially expressed (log2 fold-change &amp;gt; 1; ANOVA p &amp;lt; 0.05) between diseased patients (CRC and high-risk adenomas) relative to the healthy cohort. Internal 10-fold cross-validation was performed for the training set and a receiver operating characteristic (ROC) area under the curve (AUC) determined model accuracy for cancer and high-risk adenomas relative to the healthy cohort. Model predictions for an independent hold-out test set were used to determine model accuracy for colorectal cancer and high-risk adenomas. Internal cross-validation for 154 samples attained a ROC AUC of 0.82. The trained model was employed on the independent hold-out test set of 36 samples and model predictions were compared to colonoscopy results. The model attained a 100% sensitivity for CRC (n = 7), a 60% sensitivity for high-risk adenomas (n = 5), and an 88% combined specificity for the healthy cohort (n = 24). CRC-SDT uses 12 biomarkers (FIT and expression from 11 seRNA transcripts) to accurately detect CRC and high-risk adenomas. Use of seRNA biomarkers dramatically improves detection of high-risk adenomas relative to existing noninvasive screening methods for CRC. Citation Format: Erica K. Barnell, Yiming Kang, Katie M. Campbell, Kimberly R. Kruse, Andrew R. Barnell, Elizabeth M. Wurtzler. Stool-derived eukaryotic RNA (seRNA) assay for noninvasive detection of colorectal cancer and high-risk adenomas [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4213.
Table of Contents
Authors: Kitty Jager, Csaba Kovesdy, Robyn Langham, Mark Rosenberg, Vivekanand Jha, Carmine Zoccali, Daniel Edmonston, Christina Wyatt, Sana Al-Khatib, Madhav Menon, Niralee Patel, John Cijiang He, Marciana Laster, Renata Pereira, Isidro Salusky, Silvia Leon, Navdeep Tangri, Chirag Parikh, Steven Coca, Cédric Rafat, Yosu Luque, Susan Mendley, Adeera Levin, Ricardo Correa-Rotter, Bonnie Joubert, Elizabeth Whelan, Brian Curwin, Erik Koritzinsky, Denise Gaughan, Paul Kimmel, Shuchi Anand, Pedro Ordunez, Ludovic Reveiz, Diane Rohlman, Madeleine Scammell, Robert Wright, Robert Star
Journal: Kidney International (2019)
Hodgkin's disease
Authors: R. Dorfman
Journal: JAMA (1969)

Dr. Kent Kreisman, Junior Assistant Resident in Medicine, Jewish Hospital of St. Louis, and Assistant in Medicine, Washington University School of Medicine: A 44-year-old white woman was hospitalized on March 10, 1968, with a five-day history of fever, chills, and malaise. The past history included meningitis in childhood, recurrent asthma for 17 years, and a complete hysterectomy four years prior to admission. Physical examination revealed a middle-aged woman appearing acutely ill. Pulse rate was 120 beats per minute and regular; blood pressure, 110/60 mm Hg; respiratory rate, 20 per minute; and temperature, 104 F (40 C). Findings from examination of the head, ears, eyes, nose, throat, and thorax were unremarkable. No lymph-node enlargement was detected. The liver was palpable 6 cm below the costal margin; the spleen was not felt. Findings from examination of the extremities and the nervous system were normal. Laboratory data on admission included a hematocrit reading
Propranolol
Authors: WILLIAM B. ABRAMS
Journal: Annals of Internal Medicine (1973)

Comments and Corrections1 November 1973PropranololWILLIAM B. ABRAMS, M.D., F.A.C.P.WILLIAM B. ABRAMS, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-79-5-752 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: The principal point of the recent article by Morrelli on propranolol (Ann Intern Med 78:913-917, 1973) is that the package insert is out of date. He appears to be concerned principally with new indications recommended in the literature but not included in this document. . . . I share Dr. Morrelli's opinion that the package insert does not reflect certain uses currently "unapproved."Unfortunately, some of his statements are also a bit out of date. For example, he notes that "new drugs . . . are often introduced after only limited clinical trials. . . ." Surely...References1. COLTART D and SHAND D: Plasma propranolol levels in the quantitative assessment of β-adrenergic blockade in man. Br Med J 3:731-734, 1970 CrossrefMedlineGoogle Scholar2. COLTART D, GIBSON D, and SHAND D: Plasma propranolol levels associated with suppression of ventricular ectopic beats. Br Med J 1:490-491, 1971 CrossrefMedlineGoogle Scholar3. GIBSON D, BALCON R, and SOWTON E: Clinical use of I.C.I. 50172 as an antidysrhythmic agent in heart failure. Br Med J 3:161-163, 1968 CrossrefMedlineGoogle Scholar4. SHAND D and RANGNO R: The disposition of propranolol. Pharmacology 7:159-168, 1972 CrossrefMedlineGoogle Scholar5. ZACEST R and KOCH-WESER J: Relation of propranolol plasma level to beta blockade during oral therapy. Ibid., pp. 178-185 Google Scholar6. ADELMAN A, SHAN P, and GRAMIAK R: Long-term propranolol therapy in muscular subaortic stenosis. Br Heart J 32:804-811, 1970 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: WILLIAM B. ABRAMS, M.D., F.A.C.P.Affiliations: Ayerst Laboratories New York, New York PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySynthesis of Condensed and Uncondensed Tetrazolo[1,5-b][1,2,4]triazines as Potential Antimicrobial AgentsD 1 November 1973Volume 79, Issue 5Page: 752-754KeywordsClinical trialsDrugs ePublished: 1 December 2008 Issue Published: 1 November 1973 PDF downloadLoading ...
Carcinogenicity and Toxicity of Methoxychlor
Authors: Melvin Dwaine Reuber
Journal: Environmental Health Perspectives (1980)

Methoxychlor is carcinogenic for the liver of C3H and BALB/c mice and Osborne-Mendel rats, and possibly for the liver of dogs. Methoxychlor is also carcinogenic for the testis of BALB/c male mice, bone of B6C3F1 female mice, and the ovary of Osborne-Mendel female rats. The incidences of carcinomas of the liver were increased in C3H male mice and BALB/c male and female mice fed methoxychlor. There also was an increase in malignant neoplasms at all sites in BALB/c male and female mice. C3H and BALB/c male mice were more susceptible to the carcinogenic effects of methoxychlor than were female mice. BALB/c mice were more susceptible than C3H mice. Osborne-Mendel male and female rats developed significant incidences of carcinomas of the liver. The incidence of sarcomas of the spleen and abdomen, mostly hemangiosarcomas, was increased in male rats. Neoplasms of the pituitary, adrenals, and mammary gland were also increased in methoxychlor-treated female rats. Miniature swine given methoxychlor developed chronic renal disease in relatively short periods of time. There also was hyperplasia of the mammary gland and uterus, suggesting an estrogen-like effect on those organs. Methoxychlor applied to the skin of rabbits caused a dose-related atrophy of the testes, as well as chronic renal disease. Atrophy of the testes and chronic renal disease could not be evaluated in mice and rats because of insufficient data.
Health-related quality of life in adolescents with psoriasis: an interview-based study
Authors: H. Randa, J.J. Lomholt, L. Skov, R. Zachariae
Journal: British Journal of Dermatology (2018)

Psoriasis is a common skin disease affecting the physical, psychological and social well‐being of patients and their families. Most research so far has been limited to adults, and little is known about the experiences of young people with psoriasis. The aim of this study, from Denmark, was to provide an in‐depth understanding of the impact of psoriasis on adolescents’ health‐related quality of life (HRQoL). Thirty‐sixs interviews were conducted with 18 adolescents with psoriasis (aged 12–17 years), 14 of their parents and four health professionals working with psoriasis. The interview guide included broad, open‐ended questions asking about different life domains (e.g. physical, emotional and social) rather than specific issues previously addressed in existing (e.g. questionnaire‐based) research. However, when participants raised issues previously addressed in existing questionnaires, the authors prompted them to provide more information on these issues. The participants reported that psoriasis affected their quality of life within six main themes: physical symptoms (e.g. itching and flaking, fluctuation of symptoms), feeling different (e.g. feeling alone, body image issues), psoriasis‐related worry about the future (e.g. disease worsening, education and work, starting a family), increased attention (e.g. comments, staring, bullying), attempts to conceal skin (e.g. choosing specific clothing, avoiding swimming) and treatment‐related frustrations and worry (e.g. side‐effects and inconvenience). Taken together, a broad range of the reported difficulties appeared to arise from appearance‐related concerns. The impact of psoriasis and its treatment on the adolescents’ daily lives varied considerably. The authors believe that dermatologists during consultations could help by including patients’ HRQoL concerns in planning treatment, and also simply asking about these factors. In more complicated cases, referral to psychologists or counselling might be necessary.
Reproductive Toxicity of Di-n-Butylphthalate in a Continuous Breeding Protocol in Sprague-Dawley Rats
Authors: Robert N. Wine, Ling-Hong Li, Leta Hommel Barnes, Dushyant K. Gulati, Robert E. Chapin
Journal: Environmental Health Perspectives (1997)

The phthalate ester di-n-butylphthalate (DBP) is used extensively in the manufacture of plastics; its reproductive toxicity was tested in rats by the National Toxicology Program's Reproductive Assessment by Continuous Breeding protocol. Levels of 0.1, 0.5, and 1.0% DBP in the diet were selected, and this dosing design yielded average daily DBP intakes of 52, 256, and 509 mg/kg for males and 80, 385, and 794 mg/kg for females, respectively. DBP consumption by F0 rats reduced the total number of live pups per litter in all treated groups by 8-17% and live pup weights in the 0.5% and 1.0% dose groups by < 13%. In tests to determine the affected sex, the number of offspring was unchanged, but the weights of pups from treated females were significantly decreased and offspring from treated males were unchanged. At necropsy, high-dose F0 females had a 14% reduction in body weight, and both sexes had approximately 10-15% increased kidney and liver to body weight ratios compared to controls. Sperm parameters and estrous cyclicity were not affected. In the F1 mating trial, indices of mating, pregnancy, and fertility in the 1.0% dose group were all sharply decreased (one live litter was delivered out of 20 cohabited pairs), concomitant with a 13% decrease in dam body weight. Live F2 pup weights were 6-8% lower in all dose groups. F1 necropsy results revealed that epididymal sperm counts and testicular spermatid head counts were significantly decreased in the 1.0% dose group. Histopathologic investigation showed that 8 of 10 F1 males consuming 1.0% DBP had degenerated seminiferous tubules and 5 of 10 had underdeveloped or otherwise defective epididymides. No ovarian or uterine lesions were observed. In conclusion, this study showed that DBP is a reproductive/developmental toxicant in Sprague-Dawley rats exposed both as adults and during development; it also indicates that the adverse reproductive/developmental effects of DBP on the second generation were greater than on the first generation.
Evaluating Function in Women after a Stroke Using Two Different Types of Measures
Journal: Annals of Internal Medicine (2002)

Summaries for Patients4 June 2002Evaluating Function in Women after a Stroke Using Two Different Types of MeasuresSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-11-200206040-00003 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?When health care providers are trying to determine how well a patient can function, they often just ask the patient about whether he or she has trouble with daily activities, such as eating, dressing, bathing, or walking. These types of measures are known as patient self-report. Other ways to evaluate a patient's function involve actually observing whether the patient can complete a task. These types of measures are known as performance-based tests. It is unknown which method is better for identifying patients who are having difficulty.Why did ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Clinical Assessment of Function among Women with a Recent Cerebrovascular Event: A Self-Reported versus Performance-Based Measure.” It is in the 4 June 2002 issue of Annals of Internal Medicine (volume 136, pages 802-811). The authors are P Owens, EH Bradley, SM Horwitz, CM Viscoli, WN Kernan, LM Brass, PM Sarrel, and RI Horwitz.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoClinical Assessment of Function among Women with a Recent Cerebrovascular Event: A Self-Reported versus Performance-Based Measure Pamela L. Owens , Elizabeth H. Bradley , Sarah M. Horwitz , Catherine M. Viscoli , Walter N. Kernan , Lawrence M. Brass , Philip M. Sarrel , and Ralph I. Horwitz Metrics 4 June 2002Volume 136, Issue 11Page: I-34KeywordsBrainEatingForecastingHealth care providersIschemic strokePatientsPhysical functioningStrokeTransient ischemic attacksWalking ePublished: 4 June 2002 Issue Published: 4 June 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Chronic Porphyria
Authors: A. J. Thomas
Journal: BMJ (1950)

alteration of sensation, tendon-jerks were the same on both sides, and there appeared to be no difference in the character of the radial pulse on the affected side. ConclusionA series of 25 cases of fracture of the first rib is pre- sented; these fractures had occurred in the majority of cases without symptoms, and showed a preponderance in young adults between the ages of 18 and 19.Cases that present with acute and severe symptoms conform to a characteristic clinical picture.The radiological pictpre is constant in its site, the fracture occurring always in the region of the scalene tubercle of the rib.Callus seems to be rather slow in developing on the whole, and cases of non-union are not uncommon.In no case could damage to the brachial plexus or sub- clavian artery be demonstrated clinically.
Hereditary Cancer
Authors: Alfred G. Knudson
Journal: JAMA (1979)

The report in this issue ofThe Journalby Blattner and his colleagues (p 259) contributes still further evidence that our load of cancer is not borne equally by all members of society. The members of their family who inherit the responsible dominant Mendelian gene have a high incidence of neoplasia. The neoplasms include sarcomas, brain tumors, leukemias, and breast cancer and are clearly a nonrandom segment of the spectrum of all cancers. The median age of onset for affected gene carriers is the young age of 30 years. The ages of onset are related to the neoplastic types in that their spectrum is appropriate for the observed distribution of ages. Although the predisposing gene is highly penetrating, there are some persons, notably subject II-35, who clearly carried the mutant gene but did not have a cancer at early age, although subject II-35 may have died of prostatic cancer. Other
Leads from the MMWR. Congo-Crimean hemorrhagic fever--Republic of South Africa
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lord Moynihan (1865-1936) British provincial surgeon
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal